Clinical Cardiovascular Research Center, University of Rochester, Rochester, New York, USA.
Clinical Cardiovascular Research Center, University of Rochester, Rochester, New York, USA.
JACC Clin Electrophysiol. 2023 Jul;9(7 Pt 1):979-988. doi: 10.1016/j.jacep.2022.11.020. Epub 2023 Jan 18.
The benefit of implantable cardioverter-defibrillators (ICDs) in elderly patients is controversial.
The aims of this study were to evaluate the risk for ventricular tachyarrhythmia (VTA) and ICD shocks by age groups and to assess the competing risk for VTA and death without prior VTA.
The study included 5,170 primary prevention ICD recipients enrolled in 5 landmark ICD trials (MADIT [Multicenter Automatic Defibrillator Implantation Trial] II, MADIT-Risk, MADIT-CRT [MADIT Cardiac Resynchronization Therapy], MADIT-RIT [MADIT Reduce Inappropriate Therapy], and RAID [Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillator]). Fine and Gray regression analysis was used to evaluate the risk for fast VTA (ventricular tachycardia ≥200 beats/min or ventricular fibrillation) vs death without prior fast VTA in 3 prespecified age groups: <65, 65 to <75, and ≥75 years.
The cumulative incidence of fast VTA at 3 years was similar for patients <65 years of age and those 65 to <75 years of age (17% vs 15%) and was lowest among patients ≥75 years of age (10%) (P < 0.001). Multivariate Fine and Gray analysis showed a 40% lower risk for fast VTA in patients ≥75 years of age (HR: 0.60; 95% CI: 0.46-0.78; P < 0.001) compared with patients <65 years of age. In patients ≥75 years of age, a risk reversal was observed whereby the risk for death without prior fast VTA exceeded the risk for developing fast VTA. A history of nonsustained ventricular tachycardia, male sex, and the presence of nonischemic cardiomyopathy were identified as predictors of fast VTA in patients ≥75 years of age.
Patients ≥75 years of age have a significantly lower risk for VTA and ICD shocks compared with younger patients. Aging is associated with a higher risk for death compared with the risk for fast VTA, the reverse of what is seen in younger patients.
植入式心脏复律除颤器(ICD)在老年患者中的益处存在争议。
本研究旨在通过年龄组评估室性心动过速(VTA)和 ICD 电击的风险,并评估无先前 VTA 情况下 VTA 和死亡的竞争风险。
该研究纳入了 5 项标志性 ICD 试验(MADIT [多中心自动除颤器植入试验] II、MADIT-Risk、MADIT-CRT [MADIT 心脏再同步治疗]、MADIT-RIT [MADIT 减少不适当治疗]和 RAID [雷诺嗪在植入式心脏复律除颤器高危患者中的应用])中的 5170 例原发性预防 ICD 接受者。精细和灰色回归分析用于评估 3 个预设年龄组(<65 岁、65-<75 岁和≥75 岁)中快速 VTA(室性心动过速≥200 次/分或心室颤动)与无先前快速 VTA 死亡的风险。
<65 岁和 65-<75 岁年龄组患者的 3 年快速 VTA 累积发生率相似(17%比 15%),而≥75 岁年龄组患者的发生率最低(10%)(P<0.001)。多变量精细和灰色分析显示,≥75 岁患者发生快速 VTA 的风险降低了 40%(HR:0.60;95%CI:0.46-0.78;P<0.001)。在≥75 岁的患者中,观察到风险逆转,即无先前快速 VTA 死亡的风险超过了发生快速 VTA 的风险。非持续性室性心动过速史、男性和非缺血性心肌病的存在被确定为≥75 岁患者发生快速 VTA 的预测因素。
与年轻患者相比,≥75 岁的患者 VTA 和 ICD 电击的风险显著降低。与年轻患者相反,衰老与死亡风险相关,而与快速 VTA 风险相关。